Skip to main content

Dr. John Mathews

Medical Oncology (Medical Oncology Physician)

  • Medicare participating

At a glance

Years since graduation
18
In the NPI registry since
2010
Medicare patients seen, 2024
390

Licensed in Texas since 2014, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is

Education and training

  • 2010Registered with an NPI (national billing number; not a license date)

Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Medical Oncology Physician primary
    TX license Q1216 (first issued 2014; active)
  • Internal Medicine Physician
    TX license BP1-0031780

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Medical Oncology per capita by county →

Where they work

Hospitals

Medical groups

Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.

Medicare patients and services

Medicare patients, 2024
390
Services billed
45,907
Patients’ average age
70
Most frequent Medicare services, 2023
ServiceTimesPatients
Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes2,017180
Blood test, comprehensive group of blood chemicals892154
Magnesium level890154
Lactate dehydrogenase (enzyme) level884154
Injection, dexamethasone sodium phosphate, 1 mg60526
Phosphate level578113
Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count566130
Established patient office or other outpatient visit, 30-39 minutes540141
Insertion of needle into vein for collection of blood sample415117
Complete blood cell count (red cells, white blood cell, platelets), automated test33090

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 10 companies reported 28 payments worth $655 in total to this clinician.

By type
Food and Beverage$488
Education$167

What the payments were for

Largest payments other than meals
DateCompanyWhat it was forAmount
Dec 16, 2025AbbVie Inc.
Dec 16, 2025
Education
IMBRUVICA · ONCOLOGY · in-kind
$99.00
Jan 16, 2025AbbVie Inc.
Jan 16, 2025
Education
CREON · ENDOCRINOLOGY · in-kind
$9.65
Feb 17, 2025AbbVie Inc.
Feb 17, 2025
Education
CREON · ENDOCRINOLOGY · in-kind
$9.65
Apr 8, 2025AbbVie Inc.
Apr 8, 2025
Education
CREON · ENDOCRINOLOGY · in-kind
$9.65
Aug 20, 2025AbbVie Inc.
Aug 20, 2025
Education
CREON · ENDOCRINOLOGY · in-kind
$9.65
Sep 16, 2025AbbVie Inc.
Sep 16, 2025
Education
CREON · ENDOCRINOLOGY · in-kind
$9.65
Nov 10, 2025AbbVie Inc.
Nov 10, 2025
Education
CREON · ENDOCRINOLOGY · in-kind
$9.65
Dec 15, 2025AbbVie Inc.
Dec 15, 2025
Education
CREON · ENDOCRINOLOGY · in-kind
$9.65

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Texas →

Industry-funded research

Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $26,843 in research payments for these studies, mostly to the institutions running them.

  • Expanded Access Protocol (EAP) of subjects receiving nonconforming lisocabtagene maraleucel that is out of specification (OOS) for commercial release
    E.r. Squibb & Sons, L.l.c.

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Medical Oncology clinicians in Dallas

Sources

NPI registry (CMS NPPES, November 2026; record last updated September 22, 2025), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1568776391. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.